Patients with smoldering multiple myeloma (SMM), an asymptomatic form of myeloma, do not benefit from treatment with the anti-ICAM1 antibody BI-505, according to the results…
A Phase 1 trial will soon be assessing Actimab-M, an anti-CD33 antibody bound to a radioactive compound, in heavily treated multiple myeloma patients, the compound’s developer,…
People with chronic diseases value the Affordable Care Act (ACA), commonly known as Obamacare, more than Americans in general, a survey by PatientsLikeMe has found. They are also…
A new immunotherapy using natural killer cells showed promise in a small proof-of-concept Phase 1 trial of relapsed or refractory multiple myeloma patients who also…
Multiple myeloma patients older than 65 years benefit as much as younger patients from autologous stem cell transplant (ASCT), according to a recent retrospective study.
A combination treatment of four drugs including the chemotherapy agent Alkeran (melphalan) gives excellent short-term outcomes in multiple myeloma patients who undergo stem cell transplants,…
The use of Revlimid (lenalidomide) as a maintenance therapy for adult patients with newly diagnosed multiple myeloma who underwent autologous stem cell transplant (ASCT)…
Combination treatment with Velcade (bortezomib) and Thalomid (thalidomide) may significantly improve survival of multiple myeloma patients who received a stem cell transplant, according to recent…
Cellectar Biosciences has been granted a U.S. patent for the method of use for the compounds CLR 131 and CLR 125 in the treatment of…
Patients with bone metastasis due to multiple myeloma, breast or prostate cancer, who received zoledronic acid every 12 weeks for two years, did not have increased risk of skeletal-related events…